1
|
Philipova I, Mihaylova R, Momekov G, Angelova R, Stavrakov G. Ferrocene modified analogues of imatinib and nilotinib as potent anti-cancer agents. RSC Med Chem 2023; 14:880-889. [PMID: 37252096 PMCID: PMC10211329 DOI: 10.1039/d3md00030c] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2023] [Accepted: 03/13/2023] [Indexed: 03/16/2024] Open
Abstract
The unique features of ferrocene and the need for development of targeted anticancer drugs inspired the design, synthesis and biological evaluation of ferrocenyl modified tyrosine kinase inhibitors by replacing the pyridyl moiety in imatinib and nilotinib generalized structures with a ferrocenyl group. A series of seven new ferrocene analogues were synthesized and evaluated for their anticancer activity in a panel of bcr-abl positive human malignant cell lines using imatinib as a reference drug. The metallocenes exhibited a dose-dependent inhibition on malignant cell growth with varying antileukemic activity. The most potent analogues were compounds 9 and 15a showing comparable or even superior efficacy to the reference. Their cancer selectivity indices suggest a favorable selectivity profile, indicating a 250 times higher preferential activity of 15a towards malignantly transformed K-562 cells and an even twice greater one (500) of 9 in the LAMA-84 leukemic model as compared to the normal murine fibroblast cell line.
Collapse
Affiliation(s)
- Irena Philipova
- Institute of Organic Chemistry with Centre of Phytochemistry, Bulgarian Academy of Sciences Acad. G. Bontchev str. Bl. 9 1113 Sofia Bulgaria
| | - Rositsa Mihaylova
- Faculty of Pharmacy, Medical University - Sofia Dunav str. 2 Sofia 1000 Bulgaria
| | - Georgi Momekov
- Faculty of Pharmacy, Medical University - Sofia Dunav str. 2 Sofia 1000 Bulgaria
| | - Rostislava Angelova
- Faculty of Pharmacy, Medical University - Sofia Dunav str. 2 Sofia 1000 Bulgaria
| | - Georgi Stavrakov
- Institute of Organic Chemistry with Centre of Phytochemistry, Bulgarian Academy of Sciences Acad. G. Bontchev str. Bl. 9 1113 Sofia Bulgaria
- Faculty of Pharmacy, Medical University - Sofia Dunav str. 2 Sofia 1000 Bulgaria
| |
Collapse
|
2
|
Biegański P, Kovalski E, Israel N, Dmitrieva E, Trzybiński D, Woźniak K, Vrček V, Godel M, Riganti C, Kopecka J, Lang H, Kowalski K. Electronic Coupling in 1,2,3-Triazole Bridged Ferrocenes and Its Impact on Reactive Oxygen Species Generation and Deleterious Activity in Cancer Cells. Inorg Chem 2022; 61:9650-9666. [PMID: 35699521 PMCID: PMC9490837 DOI: 10.1021/acs.inorgchem.2c01110] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/04/2022]
Abstract
![]()
Mixed-valence (MV)
binuclear ferrocenyl compounds have long been
studied as models for testing theories of electron transfer and in
attempts to design molecular-scale electronic devices (e.g., molecular wires). In contrary to that, far less attention has
been paid to MV binuclear ferrocenes as anticancer agents. Herein,
we discuss the synthesis of six 1,2,3-triazole ferrocenyl compounds
for combined (spectro)electrochemical, electron paramagnetic resonance
(EPR), computational, and anticancer activity studies. Our synthetic
approach was based on the copper-catalyzed 1,3-dipolar azide–alkyne
cycloaddition reaction and enabled us to obtain in one step compounds
bearing either one, two, or three ferrocenyl entities linked to the
common 1,2,3-triazole core. Thus, two series of complexes were obtained,
which pertain to derivatives of 3′-azido-3′-deoxythymidine
(AZT) and 3-azidopropionylferrocene, respectively. Based on the experimental
and theoretical data, the two mono-oxidized species corresponding
to binuclear AZT and trinuclear 3-azidopropionylferrocene complexes
have been categorized as class II mixed-valence according to the classification
proposed by Robin and Day. Of importance is the observation that these
two compounds are more active against human A549 and H1975 non-small-cell
lung cancer cells than their congeners, which do not show MV characteristics.
Moreover, the anticancer activity of MV species competes or surpasses,
dependent on the cell line, the activity of reference anticancer drugs
such as cisplatin, tamoxifen, and 5-fluorouracil. The most active
from the entire series of compounds was the binuclear thymidine derivative
with the lowest IC50 value of 5 ± 2 μM against
lung H1975 cancer cells. The major mechanism of antiproliferative
activity for the investigated MV compounds is based on reactive oxygen
species generation in cancer cells. This hypothesis was substantiated
by EPR spin-trapping experiments and the observation of decreased
anticancer activity in the presence of N-acetyl cysteine
(NAC) free-radical scavenger. The
1,2,3-triazole bridged bi- and triferrocenyl compounds
were prepared via a “click” reaction.
Their corresponding mono-oxidized forms have been categorized as class
II MV species. The biferrocenyl thymidine derivative showed remarkable
anticancer activity against human A549 and H1975 cancer cells and
negligible activity against nonmalignant human BEAS-2B cells. The
anticancer activity mechanism is mainly due to ROS generation, and
it originates from the combination of electronic coupling and the
thymidine moiety, combined all together in one molecular scaffold.
Collapse
Affiliation(s)
- Przemysław Biegański
- Department of Organic Chemistry, Faculty of Chemistry, University of Łódź, Tamka 12, 91-403 Łódź, Poland
| | - Eduard Kovalski
- Institut für Chemie, Anorganische Chemie, Fakultät für Naturwissenschaften, Technische Universität Chemnitz, Straße der Nationen 62, D-09107 Chemnitz, Germany
| | - Noel Israel
- Leibniz Institute for Solid State and Materials Research (IFW Dresden), Helmholtzstraße 20, D-01069 Dresden, Germany
| | - Evgenia Dmitrieva
- Leibniz Institute for Solid State and Materials Research (IFW Dresden), Helmholtzstraße 20, D-01069 Dresden, Germany
| | - Damian Trzybiński
- Faculty of Chemistry, Biological and Chemical Research Centre, University of Warsaw, Żwirki i Wigury 101, 02-089 Warszawa, Poland
| | - Krzysztof Woźniak
- Faculty of Chemistry, Biological and Chemical Research Centre, University of Warsaw, Żwirki i Wigury 101, 02-089 Warszawa, Poland
| | - Valerije Vrček
- Department of Organic Chemistry, Faculty of Pharmacy and Biochemistry, University of Zagreb, 10000 Zagreb, Croatia
| | - Martina Godel
- Department of Oncology, University of Torino, via Santena 5/bis, 10126 Turin, Italy
| | - Chiara Riganti
- Department of Oncology, University of Torino, via Santena 5/bis, 10126 Turin, Italy
| | - Joanna Kopecka
- Department of Oncology, University of Torino, via Santena 5/bis, 10126 Turin, Italy
| | - Heinrich Lang
- Institut für Chemie, Anorganische Chemie, Fakultät für Naturwissenschaften, Technische Universität Chemnitz, Straße der Nationen 62, D-09107 Chemnitz, Germany.,MAIN Research Center, Technische Universität Chemnitz, Rosenbergstraße 6, 09126 Chemnitz, Germany
| | - Konrad Kowalski
- Department of Organic Chemistry, Faculty of Chemistry, University of Łódź, Tamka 12, 91-403 Łódź, Poland
| |
Collapse
|
3
|
A prodrug of 3-(ferrocenylaminocarbonyloxymethyl)phenol activated by reactive oxygen species in cancer cells. J Inorg Biochem 2022; 233:111859. [DOI: 10.1016/j.jinorgbio.2022.111859] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2022] [Revised: 04/11/2022] [Accepted: 05/08/2022] [Indexed: 11/22/2022]
|
4
|
Jadhav J, Das R, Kamble S, Chowdhury MG, Kapoor S, Gupta A, Vyas H, Shard A. Ferrocene-Based Modulators of Cancer-Associated Tumor Pyruvate Kinase M2. J Organomet Chem 2022. [DOI: 10.1016/j.jorganchem.2022.122338] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
5
|
Xu HG, Annamadov S, Mokhir A. 4-Ferrocenylaniline-based ROS-responsive prodrugs with anticancer activity. J Organomet Chem 2022. [DOI: 10.1016/j.jorganchem.2022.122305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
6
|
Schoch S, Braccini S, Biancalana L, Pratesi A, Funaioli T, Zacchini S, Pampaloni G, Chiellini F, Marchetti F. When ferrocene and diiron organometallics meet: triiron vinyliminium complexes exhibit strong cytotoxicity and cancer cell selectivity. Inorg Chem Front 2022. [DOI: 10.1039/d2qi00534d] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Robust and versatile cationic triiron complexes, obtained from the assembly of ferrocenyl with a di-organoiron structure, display an outstanding cytotoxicity profile, which may be related to redox processes provided by the two metallic components.
Collapse
Affiliation(s)
- Silvia Schoch
- University of Pisa, Department of Chemistry and Industrial Chemistry, Via G. Moruzzi 13, I-56124 Pisa, Italy
| | - Simona Braccini
- University of Pisa, Department of Chemistry and Industrial Chemistry, Via G. Moruzzi 13, I-56124 Pisa, Italy
| | - Lorenzo Biancalana
- University of Pisa, Department of Chemistry and Industrial Chemistry, Via G. Moruzzi 13, I-56124 Pisa, Italy
| | - Alessandro Pratesi
- University of Pisa, Department of Chemistry and Industrial Chemistry, Via G. Moruzzi 13, I-56124 Pisa, Italy
| | - Tiziana Funaioli
- University of Pisa, Department of Chemistry and Industrial Chemistry, Via G. Moruzzi 13, I-56124 Pisa, Italy
| | - Stefano Zacchini
- University of Bologna, Department of Industrial Chemistry “Toso Montanari”, Viale Risorgimento 4, I-40136 Bologna, Italy
| | - Guido Pampaloni
- University of Pisa, Department of Chemistry and Industrial Chemistry, Via G. Moruzzi 13, I-56124 Pisa, Italy
| | - Federica Chiellini
- University of Pisa, Department of Chemistry and Industrial Chemistry, Via G. Moruzzi 13, I-56124 Pisa, Italy
| | - Fabio Marchetti
- University of Pisa, Department of Chemistry and Industrial Chemistry, Via G. Moruzzi 13, I-56124 Pisa, Italy
| |
Collapse
|
7
|
Xu HG, Reshetnikov V, Wondrak M, Eckhardt L, Kunz-Schughart LA, Janko C, Tietze R, Alexiou C, Borchardt H, Aigner A, Gong W, Schmitt M, Sellner L, Daum S, Özkan HG, Mokhir A. Intracellular Amplifiers of Reactive Oxygen Species Affecting Mitochondria as Radiosensitizers. Cancers (Basel) 2021; 14:208. [PMID: 35008371 PMCID: PMC8750417 DOI: 10.3390/cancers14010208] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2021] [Revised: 12/27/2021] [Accepted: 12/29/2021] [Indexed: 02/07/2023] Open
Abstract
Radiotherapy (RT) efficacy can be improved by using radiosensitizers, i.e., drugs enhancing the effect of ionizing radiation (IR). One of the side effects of RT includes damage of normal tissue in close proximity to the treated tumor. This problem can be solved by applying cancer specific radiosensitizers. N-Alkylaminoferrocene-based (NAAF) prodrugs produce reactive oxygen species (ROS) in cancer cells, but not in normal cells. Therefore, they can potentially act as cancer specific radiosensitizers. However, early NAAF prodrugs did not exhibit this property. Since functional mitochondria are important for RT resistance, we assumed that NAAF prodrugs affecting mitochondria in parallel with increasing intracellular ROS can potentially exhibit synergy with RT. We applied sequential Cu+-catalyzed alkyne-azide cycloadditions (CuAAC) to obtain a series of NAAF derivatives with the goal of improving anticancer efficacies over already existing compounds. One of the obtained prodrugs (2c) exhibited high anticancer activity with IC50 values in the range of 5-7.1 µM in human ovarian carcinoma, Burkitt's lymphoma, pancreatic carcinoma and T-cell leukemia cells retained moderate water solubility and showed cancer specificity. 2c strongly affects mitochondria of cancer cells, leading to the amplification of mitochondrial and total ROS production and thus causing cell death via necrosis and apoptosis. We observed that 2c acts as a radiosensitizer in human head and neck squamous carcinoma cells. This is the first demonstration of a synergy between the radiotherapy and NAAF-based ROS amplifiers.
Collapse
Affiliation(s)
- Hong-Gui Xu
- Organic Chemistry Chair II, Department of Chemistry and Pharmacy, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Nikolaus-Fiebiger-Str. 10, 91058 Erlangen, Germany; (H.-G.X.); (V.R.); (S.D.); (H.G.Ö.)
| | - Viktor Reshetnikov
- Organic Chemistry Chair II, Department of Chemistry and Pharmacy, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Nikolaus-Fiebiger-Str. 10, 91058 Erlangen, Germany; (H.-G.X.); (V.R.); (S.D.); (H.G.Ö.)
| | - Marit Wondrak
- OncoRay—National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden and Helmholtz-Zentrum Dresden—Rossendorf, 01307 Dresden, Germany; (M.W.); (L.E.); (L.A.K.-S.)
| | - Lisa Eckhardt
- OncoRay—National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden and Helmholtz-Zentrum Dresden—Rossendorf, 01307 Dresden, Germany; (M.W.); (L.E.); (L.A.K.-S.)
| | - Leoni A. Kunz-Schughart
- OncoRay—National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden and Helmholtz-Zentrum Dresden—Rossendorf, 01307 Dresden, Germany; (M.W.); (L.E.); (L.A.K.-S.)
- National Center for Tumor Diseases (NCT), Partner Site Dresden, 01307 Dresden, Germany
| | - Christina Janko
- Department of Otorhinolaryngology, Head and Neck Surgery, Section of Experimental Oncology and Nanomedicine (SEON), Universitätsklinikum Erlangen, 91054 Erlangen, Germany; (C.J.); (R.T.); (C.A.)
| | - Rainer Tietze
- Department of Otorhinolaryngology, Head and Neck Surgery, Section of Experimental Oncology and Nanomedicine (SEON), Universitätsklinikum Erlangen, 91054 Erlangen, Germany; (C.J.); (R.T.); (C.A.)
| | - Christoph Alexiou
- Department of Otorhinolaryngology, Head and Neck Surgery, Section of Experimental Oncology and Nanomedicine (SEON), Universitätsklinikum Erlangen, 91054 Erlangen, Germany; (C.J.); (R.T.); (C.A.)
| | - Hannes Borchardt
- Rudolf-Boehm-Institute for Pharmacology and Toxicology, Clinical Pharmacology, Faculty of Medicine, Leipzig University, 04107 Leipzig, Germany; (H.B.); (A.A.)
| | - Achim Aigner
- Rudolf-Boehm-Institute for Pharmacology and Toxicology, Clinical Pharmacology, Faculty of Medicine, Leipzig University, 04107 Leipzig, Germany; (H.B.); (A.A.)
| | - Wenjie Gong
- Department of Medicine V, Heidelberg University Hospital, 69120 Heidelberg, Germany; (W.G.); (M.S.); (L.S.)
- Department of Hematology, First Affiliated Hospital of Soochow University, Suzhou 215006, China
| | - Michael Schmitt
- Department of Medicine V, Heidelberg University Hospital, 69120 Heidelberg, Germany; (W.G.); (M.S.); (L.S.)
| | - Leopold Sellner
- Department of Medicine V, Heidelberg University Hospital, 69120 Heidelberg, Germany; (W.G.); (M.S.); (L.S.)
- Takeda Pharmaceuticals, Cambridge, MA 02139, USA
| | - Steffen Daum
- Organic Chemistry Chair II, Department of Chemistry and Pharmacy, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Nikolaus-Fiebiger-Str. 10, 91058 Erlangen, Germany; (H.-G.X.); (V.R.); (S.D.); (H.G.Ö.)
- Merck, Im Laternenacker 5, 8200 Schaffhausen, Switzerland
| | - Hülya Gizem Özkan
- Organic Chemistry Chair II, Department of Chemistry and Pharmacy, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Nikolaus-Fiebiger-Str. 10, 91058 Erlangen, Germany; (H.-G.X.); (V.R.); (S.D.); (H.G.Ö.)
| | - Andriy Mokhir
- Organic Chemistry Chair II, Department of Chemistry and Pharmacy, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Nikolaus-Fiebiger-Str. 10, 91058 Erlangen, Germany; (H.-G.X.); (V.R.); (S.D.); (H.G.Ö.)
| |
Collapse
|